Slide 1: https://ir.lanternpharma.com/
https://ir.lanternpharma.com/
Slide 2: Forward-Looking Statements
LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, stateme
Slide 3: Agenda
1. Business Overview & Background 2. Financial Results & IPO Summary 3. Future Outlook & Milestones 4. Q&A Session 3
Slide 4: Lantern at the forefront of AI-driven transformation in personalized oncology
10 ✦ ✦ ✦ ✦ ✦ ✦ ✦ ✦ ✦ ✦ Lantern is at the forefront of this model of A.I. driven transformation in the area of personalized oncology drug development to drive value for cancer patients and our investors. 4
Slide 5: RADR Platform Key Features & Architecture
RADR® Platform Key Features & Architecture RADR® 1 RADR® Platform Continues to Grow in Volume and Functionality 5
Slide 6: RADR Platform Continues to Grow in Volume and Functionality
RADR® ● ● ● ● ● ● ● 10 Million > 125 Million > 400 Million > 1 Billion > 3-5 Billion > ● 2018 2019 2020 2021 2022 ● 6
Slide 7: Biomarker Signature Output & Signature Development Process
Biomarker Signature is Based on Statistical Significance and Biological Relevance RADR® Output & Signature Development Process 7
Slide 8: The RADR Platform Enables...
The RADR Platform Enables... 1. Rapid identification of potential compounds to RADR rescue and develop Scientific Value + 2. Improved and more nuanced understanding of responder groups, and non-responder groups based on biological networks 3. Feedback for potential mechanisms to be exploited in target
Slide 9: Pipeline by Indication and Drug
Indication Drug R&D Preclinical Phase I Phase II Phase III Prostate Cancer LP-100 Successfully partnered & out-licensed Targeting a sub-population in Non-Small Cell Lung Cancer LP-300 NSCLC of Adenocarcinoma (Focused on Never-Smokers) subtype Solid Tumors (Location agnostic tumors identified by RADR®
Slide 10: Operating Expenses and Net Loss
Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Operating expenses: General and administrative 676,399 268,120 1,016,571 536,049 Research and development 157,023 361,273 294,127 547,317 Total operating expenses 833,422 629,393 1,310,698 1,083,366 NET LOSS $ (833,422) $ (629
Slide 11: IPO Summary and Capitalization
Date Closed: June 15, 2020 Shares Sold: 1,750,000 shares Price: $15.00 per share LANTERN PHARMA INC. ( Nasdaq : LTRN) Gross Proceeds Common Shares Outstanding 6,217,577 $26,250,000 USD Warrants (Weighted Average Exercise Price of $3.13) 262,014 Net Proceeds Underwriter Warrants (Exercise Price at $1
Slide 12: Balance Sheet (Unaudited)
06/30/2020 12/31/2019 (Unaudited) Cash $ 23,798,343 $1,232,030 Other Current Asset $1,728,539 - Prepaid Expense $70,775 $788 Total Assets $ 25,613,034 $ 1,432,576 Total Liabilities $ 2,385,165 $ 489,292 Total Stockholders’ Equity $ 23,227,869 $ 943,284 12
Slide 13: Milestones: Second Half of 2020 and 2021-22
Foundational Year Multiple Streams of Value Creation Second Half of 2020 2021-22 ● Advances for launch of LP-184 IND-Enabling studies ● Readout from targeted Ph. 2 trial in Europe in prostate cancer by first half of 2021 with LP-100 ● Data from collaboration with Georgetown in Prostate and Pancreatic
Slide 14: Virtual Conferences Schedule July to Sept.
7/31/20 LD Micro -- “Zooming with L.D.” 8/24 - 8/27/20 World Orphan Drug Congress USA Virtual Conferences Schedule July to Sept. 9/8 - 9/10/20 MedInvest A.I., Big Data & Digital Health Conference LTRN 9/10/20 Colliers 5th Annual Institutional Investor Conference 9/14 - 9/16/20 H.C. Wainwright & Co.
Slide 15: Q&A
Q&A LTRN Operating & Financial Results Call July 30, 2020 15